Outreach training needed.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Alan I Leshner.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Dramatic advances in neuroscience have created fast-rising expectations for improvements in the health and well-being of people around the world. But fulfilling this promise is proving to be neither quick nor easy, and not for scientific reasons alone. Alan Leshner urges that neuroscientists not only address the significant challenges of their own investigations but also be willing to participate in ethical and legal dialogues with colleagues and non-colleagues alike.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Studies of drugs and behavior are a core component of virtually every portfolio within the broad purview of the National Institute on Drug Abuse (NIDA). Moreover, psychopharmacological research is an important vehicle for advancing understanding of how drugs of abuse produce their effects, particularly including addiction. However, as with all major public health issues, simply understanding the issue is not enough. NIDA's psychopharmacology projects, therefore, span basic, clinical, and applied (e.g., medication development) research activities. These include the establishment of a nationwide clinical trials network designed to provide an infrastructure to test both behavioral and psychopharmacological treatments in a real-life practice setting with diverse patients.
Explore the source record for details and available documents.
Explore the source record for details and available documents.